Compare SLNG & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | ADAG |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.0M | 84.8M |
| IPO Year | N/A | 2021 |
| Metric | SLNG | ADAG |
|---|---|---|
| Price | $4.51 | $1.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.00 | $8.00 |
| AVG Volume (30 Days) | 6.2K | ★ 46.8K |
| Earning Date | 02-24-2026 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $72,270,000.00 | $103,204.00 |
| Revenue This Year | $7.02 | $6,983.06 |
| Revenue Next Year | $7.68 | $36.05 |
| P/E Ratio | $80.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.29 | $1.30 |
| 52 Week High | $8.28 | $3.16 |
| Indicator | SLNG | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 39.71 |
| Support Level | $4.33 | $1.64 |
| Resistance Level | $4.65 | $1.83 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 49.45 | 6.90 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.